CLINUVEL PHARMAC.ADRS1
Research CLINUVEL PHARMAC.ADRS1 (UR9A) on Bullrun: market cap EUR 297.52M, P/E 15.1, dividend yield 0.5%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerUR9A
- ExchangeF
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 297.52M
- P/E15.1
- Dividend yield0.5%
- Financial periodFY2025
- RevenueEUR 95.02M
- Revenue growth7.8%
- Net incomeEUR 36.17M
- Free cash flowEUR 40.80M
- Gross margin83.3%
Valuation Snapshot
latest market cap is EUR 297.52M; P/E is 15.1; dividend yield is 0.5%.
About CLINUVEL PHARMAC.ADRS1
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).
Frequently asked questions
What is CLINUVEL PHARMAC.ADRS1's market cap?
CLINUVEL PHARMAC.ADRS1's market capitalization is EUR 297.52M.
What is CLINUVEL PHARMAC.ADRS1's P/E ratio?
CLINUVEL PHARMAC.ADRS1's price-to-earnings (P/E) ratio is 15.1.
Does CLINUVEL PHARMAC.ADRS1 pay a dividend?
CLINUVEL PHARMAC.ADRS1 has a dividend yield of 0.5%.
What does CLINUVEL PHARMAC.ADRS1 do?
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.